{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:06:29Z","timestamp":1790510789582,"version":"4.1.0"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T00:00:00Z","timestamp":1476921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0165336","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T17:50:24Z","timestamp":1476985824000},"page":"e0165336","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":49,"title":["Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment"],"prefix":"10.1371","volume":"11","author":[{"given":"Lasse","family":"Kj\u00e6r","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Cordua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten O.","family":"Holmstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Thomassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben A","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Pallisgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"de Stricker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibe","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C.","family":"Hasselbalch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,10,20]]},"reference":[{"issue":"7","key":"ref1","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/leu.2014.35","article-title":"An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms","volume":"28","author":"A Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"25","key":"ref2","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"T Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"ref3","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"J Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"ref4","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"E Rumi","year":"2014","journal-title":"Blood"},{"issue":"7","key":"ref5","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3324\/haematol.2014.107482","article-title":"Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations","volume":"99","author":"H Andrikovics","year":"2014","journal-title":"Haematologica"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"G Rotunno","year":"2014","journal-title":"Blood"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1038\/leu.2014.49","article-title":"Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis","volume":"28","author":"J Broseus","year":"2014","journal-title":"Leukemia"},{"issue":"26","key":"ref8","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1182\/blood-2014-06-583161","article-title":"Presence of calreticulin mutations in JAK2-negative polycythemia vera","volume":"124","author":"J Broseus","year":"2014","journal-title":"Blood"},{"issue":"7","key":"ref9","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJMc1413718","article-title":"A CALR mutation preceding BCR-ABL1 in an atypical myeloproliferative neoplasm","volume":"372","author":"X Cabagnols","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/bjh.12969","article-title":"JAK2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort","volume":"167","author":"G McGaffin","year":"2014","journal-title":"Br J Haematol"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ejh.12578","article-title":"Molecular diagnostics of myeloproliferative neoplasms","volume":"95","author":"SE Langabeer","year":"2015","journal-title":"Eur J Haematol"},{"key":"ref12","article-title":"Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis","author":"C Marty","year":"2015","journal-title":"Blood"},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms","volume":"30","author":"D Pietra","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/leu.2014.270","article-title":"Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution","volume":"29","author":"X Cabagnols","year":"2015","journal-title":"Leukemia"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1038\/bcj.2015.90","article-title":"Validation of the differential prognostic impact of type 1\/type 1-like versus type 2\/type 2-like CALR mutations in myelofibrosis","volume":"5","author":"P Guglielmelli","year":"2015","journal-title":"Blood Cancer J"},{"issue":"15","key":"ref16","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2014-07-588426","article-title":"The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants","volume":"124","author":"A Tefferi","year":"2014","journal-title":"Blood"},{"issue":"8","key":"ref17","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"JJ Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"6","key":"ref18","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","article-title":"High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a","volume":"108","author":"JJ Kiladjian","year":"2006","journal-title":"Blood"},{"issue":"8607","key":"ref19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(88)92881-4","article-title":"Recombinant interferon-alpha for treatment of polycythaemia vera","volume":"2","author":"RT Silver","year":"1988","journal-title":"Lancet"},{"issue":"9","key":"ref20","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.leukres.2013.06.012","article-title":"Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha","volume":"37","author":"T Stauffer Larsen","year":"2013","journal-title":"Leuk Res"},{"issue":"32","key":"ref21","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"A Quintas-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref22","article-title":"Clinical and molecular response to interferon alpha therapy in essential thrombocythemia patients with CALR mutations","author":"E Verger","year":"2015","journal-title":"Blood"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1056\/NEJMc1401255","article-title":"Interferon alfa therapy in CALR-mutated essential thrombocythemia","volume":"371","author":"B Cassinat","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"ref24","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/leu.2013.102","article-title":"A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression","volume":"27","author":"C Marty","year":"2013","journal-title":"Leukemia"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"102476","DOI":"10.1155\/2015\/102476","article-title":"MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives","volume":"2015","author":"HC Hasselbalch","year":"2015","journal-title":"Mediators Inflamm"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"145293","DOI":"10.1155\/2015\/145293","article-title":"Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation","volume":"2015","author":"S Hermouet","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.leukres.2014.11.019","article-title":"Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms","volume":"39","author":"AV Jones","year":"2015","journal-title":"Leuk Res"},{"issue":"5","key":"ref28","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/bjh.12904","article-title":"Assessment of CALR mutations in myelofibrosis patients, post-allogeneic stem cell transplantation","volume":"166","author":"K Haslam","year":"2014","journal-title":"Br J Haematol"},{"key":"ref29","article-title":"Quantification of the Mutant CALR Allelic Burden by Digital PCR: Application to Minimal Residual Disease Evaluation after Bone Marrow Transplantation","author":"O Mansier","year":"2015","journal-title":"J Mol Diagn"},{"issue":"10","key":"ref30","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/leu.2013.219","article-title":"Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet\/MPN&MPNr-EuroNet (COST action BM0902) study","volume":"27","author":"JV Jovanovic","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"ref31","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2007.06497.x","article-title":"The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders","volume":"136","author":"TS Larsen","year":"2007","journal-title":"Br J Haematol"},{"issue":"4","key":"ref32","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/nar\/18.4.999","article-title":"Effects of primer-template mismatches on the polymerase chain reaction: human immunodeficiency virus type 1 model studies","volume":"18","author":"S Kwok","year":"1990","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2353\/jmoldx.2010.090035","article-title":"The effect of primer-template mismatches on the detection and quantification of nucleic acids using the 5' nuclease assay","volume":"12","author":"R Stadhouders","year":"2010","journal-title":"J Mol Diagn"},{"issue":"20","key":"ref34","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference","volume":"113","author":"G Barosi","year":"2009","journal-title":"Blood"},{"issue":"8","key":"ref35","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"A Tefferi","year":"2013","journal-title":"Blood"},{"issue":"3","key":"ref36","doi-asserted-by":"crossref","first-page":"e33100","DOI":"10.1371\/journal.pone.0033100","article-title":"A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burden","volume":"7","author":"L Kjaer","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"ref37","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jmoldx.2010.10.004","article-title":"Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay","volume":"13","author":"T Kristensen","year":"2011","journal-title":"J Mol Diagn"},{"issue":"1","key":"ref38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.12075","article-title":"Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations","volume":"160","author":"AJ Bench","year":"2013","journal-title":"Br J Haematol"},{"issue":"7","key":"ref39","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/leu.2014.83","article-title":"Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact","volume":"28","author":"A Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"ref40","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1002\/ajh.23743","article-title":"Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients","volume":"89","author":"A Tefferi","year":"2014","journal-title":"Am J Hematol"},{"issue":"6","key":"ref41","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1600-0609.2007.00960.x","article-title":"The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis\u2014impact on disease phenotype","volume":"79","author":"TS Larsen","year":"2007","journal-title":"Eur J Haematol"},{"issue":"6","key":"ref42","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a","volume":"122","author":"A Quintas-Cardama","year":"2013","journal-title":"Blood"},{"issue":"11","key":"ref43","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.22663","article-title":"Clinical correlates of JAK2V617F allele burden in essential thrombocythemia","volume":"109","author":"J Kittur","year":"2007","journal-title":"Cancer"},{"issue":"14","key":"ref44","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"P Lundberg","year":"2014","journal-title":"Blood"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0165336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T18:40:38Z","timestamp":1749667238000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0165336"}},"subtitle":[],"editor":[{"given":"Ken","family":"Mills","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,10,20]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,10,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0165336","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,20]]}}}